Literature DB >> 25408588

Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study.

Se Jin Park1, Ki Soo Pai1, Jun Mo Kim2, Kwanjin Park3, Kun Suk Kim4, Sang Hoon Song4, Sungchan Park5, Sun-Ouck Kim6, Dong Soo Ryu7, Minki Baek8, Sang Don Lee9, Jung Won Lee10, Young Jae Im11, Sang Won Han11, Jae Min Chung9, Min Hyun Cho12, Tae-Sun Ha13, Won Yeol Cho14, Hong Jin Suh15.   

Abstract

We investigated the efficacy and tolerability of various anticholinergics in Korean children with non-neurogenic overactive bladder (OAB). A total of 326 children (males:females= 157:169) aged under 18 yr (mean age 7.3±2.6 yr) who were diagnosed with OAB from 2008 to 2011 were retrospectively reviewed. The mean duration of OAB symptoms before anticholinergic treatment was 16.9±19.0 months. The mean duration of medication was 5.6±7.3 months. Urgency urinary incontinence episodes per week decreased from 1.9±3.1 to 0.4±1.5 times (P<0.001). The median voiding frequency during daytime was decreased from 9.2±5.4 to 6.3±4.2 times (P<0.001). According to 3-day voiding diaries, the maximum and average bladder capacity were increased from 145.5±66.9 to 196.8±80.3 mL and from 80.8±39.6 to 121.8±56.5 mL, respectively (P<0.001). On uroflowmetry, maximum flow rate was increased from 17.6±8.4 to 20.5±8.2 mL/sec (P<0.001). Adverse effects were reported in 14 (4.3%) children and six children (1.8%) discontinued medication due to adverse effects. Our results indicate that anticholinergics are effective to improve OAB symptoms and tolerability was acceptable without severe complications in children.

Entities:  

Keywords:  Anticholinergics; Efficacy; Overactive Urinary Bladder; Tolerability; Urinary Incontinence

Mesh:

Substances:

Year:  2014        PMID: 25408588      PMCID: PMC4234924          DOI: 10.3346/jkms.2014.29.11.1550

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  17 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Evaluation of maximum voided volume in Korean children by use of a 48-h frequency volume chart.

Authors:  Sun-Ouck Kim; Kyung Do Kim; Young Sig Kim; Jun Mo Kim; Du Geon Moon; Sungchan Park; Sang Don Lee; Jae Min Chung; Won Yeol Cho
Journal:  BJU Int       Date:  2011-12-07       Impact factor: 5.588

3.  Prospective open label study of solifenacin for overactive bladder in children.

Authors:  Stéphane Bolduc; Katherine Moore; Geneviève Nadeau; Sylvie Lebel; Pascale Lamontagne; Micheline Hamel
Journal:  J Urol       Date:  2010-08-21       Impact factor: 7.450

4.  The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society.

Authors:  Tryggve Nevéus; Alexander von Gontard; Piet Hoebeke; Kelm Hjälmås; Stuart Bauer; Wendy Bower; Troels Munch Jørgensen; Søren Rittig; Johan Vande Walle; Chung-Kwong Yeung; Jens Christian Djurhuus
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

5.  Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.

Authors:  N Zinner; J Susset; M Gittelman; M Arguinzoniz; L Rekeda; F Haab
Journal:  Int J Clin Pract       Date:  2006-01       Impact factor: 2.503

6.  The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.

Authors:  Linda Cardozo; Andrew Thorpe; Juliet Warner; Manpreet Sidhu
Journal:  BJU Int       Date:  2010-02-03       Impact factor: 5.588

7.  Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study.

Authors:  Jae Min Chung; Sang Don Lee; Dong Il Kang; Dong Deuk Kwon; Kun Suk Kim; Su Yung Kim; Han Gwun Kim; Du Geon Moon; Kwan Hyun Park; Yong Hoon Park; Ki Soo Pai; Hong Jin Suh; Jung Won Lee; Won Yeol Cho; Tae Sun Ha; Sang Won Han
Journal:  Urology       Date:  2008-09-30       Impact factor: 2.649

Review 8.  Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?

Authors:  Scott A MacDiarmid
Journal:  BJU Int       Date:  2007-06       Impact factor: 5.588

Review 9.  How to choose the initial drug treatment for overactive bladder.

Authors:  Scott A MacDiarmid
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

Review 10.  Standardization and definitions in lower urinary tract dysfunction in children. International Children's Continence Society.

Authors:  J P Nørgaard; J D van Gool; K Hjälmås; J C Djurhuus; A L Hellström
Journal:  Br J Urol       Date:  1998-05
View more
  3 in total

Review 1.  Bladder and bowel dysfunction in children: An update on the diagnosis and treatment of a common, but underdiagnosed pediatric problem.

Authors:  Joana Dos Santos; Roberto I Lopes; Martin A Koyle
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

Review 2.  Pharmacotherapy for Pediatric Neurogenic Bladder.

Authors:  Paweł Kroll
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

3.  Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.

Authors:  Sang Don Lee; Jae Min Chung; Dong Il Kang; Dong Soo Ryu; Won Yeol Cho; Sungchan Park
Journal:  J Korean Med Sci       Date:  2017-02       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.